News - Research, Neurological

Filter

Current filters:

ResearchNeurological

Popular Filters

1 to 25 of 317 results

UCB reports positive Phase III results for brivaracetam in epilepsy

UCB reports positive Phase III results for brivaracetam in epilepsy

23-07-2014

Belgian drugmaker UCB says its Phase III study of brivaracetam has shown the drug reduced partial-onset…

BelgiumBRIVARACETAMEpilepsyNeurologicalPartial-onset seizurePharmaceuticalResearchUCB

Targacept trial does not show superiority of TC-1734 over donepezil

Targacept trial does not show superiority of TC-1734 over donepezil

15-07-2014

US-based clinical-stage biopharma company Targacept has announced results from a Phase IIb monotherapy…

Alzheimer's diseaseDonepezilNeurologicalPharmaceuticalResearchTargaceptTC-1734USA

Novartis collaborates with Banner Alzheimer's Inst on AD prevention study

Novartis collaborates with Banner Alzheimer's Inst on AD prevention study

15-07-2014

Swiss pharma major Novartis has set up a collaboration with US not-for-profit group the Banner Alzheimer's…

Active immunotherapyAlzheimer's diseaseEuropeNeurologicalNovartisNovartis PharmaceuticalsPharmaceuticalResearchUSA

Varenicline combined with nicotine patch improves smoking cessation rates

Varenicline combined with nicotine patch improves smoking cessation rates

09-07-2014

Combining the smoking cessation medication varenicline with nicotine replacement therapy was more effective…

ChantixNeurologicalNicotinePfizerPharmaceuticalResearchSmoking cessationUSAVarenicline

US FDA delays Allergan’s Semprana decision, approves Ozurdex

US FDA delays Allergan’s Semprana decision, approves Ozurdex

01-07-2014

US drugmaker Allergan, the subject of a hostile $53 billion takeover pursuit by Canada’s Valeant Pharmaceuticals…

AllerganBimatoprost Ophthalmic Solution 0.03% for GlaLevadexNeurologicalOphthalmicsOzurdexPharmaceuticalRegulationResearchSempranaUSA

Eisai’s Zebinix shown to be effective and well-tolerated

Eisai’s Zebinix shown to be effective and well-tolerated

30-06-2014

Once-daily Zebinix (eslicarbazepine acetate) from Japanese drug major Eisai is effective, retained and…

EisaiEuropeNeurologicalPharmaceuticalResearchZebinix

Brintellix meets primary efficacy end-point in depression study

Brintellix meets primary efficacy end-point in depression study

26-06-2014

Danish CNS drug specialist Lundbeck has announced results of the SOLUTION trial conducted in Asian patients…

BrintellixDenmarkLundbeckNeurologicalPharmaceuticalResearch

Positive Ph III results with Forest Labs’ vilazodone in GAD

24-06-2014

US drugmaker Forest Laboratories has released positive top-line results from three Phase III trials evaluating…

Forest LaboratoriesNeurologicalPharmaceuticalResearchvilazodone

Merck & Co in new accord with Bionomics for CNS research

Merck & Co in new accord with Bionomics for CNS research

24-06-2014

Australian biotech firm Bionomics has entered into a second exclusive research collaboration and license…

BionomicsBiotechnologyBNC375LicensingMerck & CoNeurologicalResearch

Roche partners in new company for MS research

Roche partners in new company for MS research

23-06-2014

Swiss drug major Roche has entered into an exclusive partnership with Inception Sciences, a drug discovery…

Inception 5Inception SciencesMergers & AcquisitionsNeurologicalPharmaceuticalResearchRocheVersant Ventures

UK Prime Minister announces drive to discover new dementia drugs in £100 million campaign

UK Prime Minister announces drive to discover new dementia drugs in £100 million campaign

19-06-2014

The UK Prime Minister David Cameron will today pledge a new drive by the UK to discover new drugs and…

DementiaNeurologicalPharmaceuticalResearchUK

GW shares rise on positive Epidiolex efficacy data

GW shares rise on positive Epidiolex efficacy data

18-06-2014

UK-based GW Pharmaceuticals has announced physician reports of efficacy and safety data from its investigational…

epidiolexGW PharmaceuticalsNeurologicalPharmaceuticalResearchUK

Isis Pharma earns $10 million milestone from Biogen

Isis Pharma earns $10 million milestone from Biogen

17-06-2014

Isis Pharmaceuticals revealed today it has earned a $10 million milestone payment from fellow US biotech…

Biogen IdecBiotechnologyFinancialIsis PharmaceuticalsNeurologicalResearch

Brintellix superior to escitalopram in improving sexual functioning for MDD patients

Brintellix superior to escitalopram in improving sexual functioning for MDD patients

17-06-2014

Danish CSN drug specialist Lundbeck has presented results about sexual functioning from a head-to-head…

BrintellixEscitalopram OxalateLundbeckMen's HealthNeurologicalPharmaceuticalResearch

Lundbeck’s Brintellix shows efficacy in cognitive function study

Lundbeck’s Brintellix shows efficacy in cognitive function study

16-06-2014

Danish CNS drug specialist Lundbeck has announced results from the CONNECT study showing that Brintellix…

BrintellixDenmarkDepressionLundbeckNeurologicalPharmaceuticalResearch

Shire agrees to FDA call for pediatric trials of Vyvanse for ADHD

Shire agrees to FDA call for pediatric trials of Vyvanse for ADHD

12-06-2014

Ireland-headquartered drugmaker Shire says it has agreed to a written request by the US Food and Drug…

NeurologicalPharmaceuticalRegulationResearchShireUSAVyvanse

Grunenthal tests innovative treatment in one of the largest clinical trials in cancer pain

Grunenthal tests innovative treatment in one of the largest clinical trials in cancer pain

10-06-2014

German family-owned drugmaker Grunenthal is investigating the efficacy and safety of the new analgesic…

cebranopadolGrunenthalMorphineNeurologicalOncologyPharmaceuticalResearch

Chiesi links with UCL to test a novel therapeutic for birth asphyxia

Chiesi links with UCL to test a novel therapeutic for birth asphyxia

10-06-2014

Privately-held Italian drugmaker Chiesi Farmaceutici has entered into a collaboration with University…

Chiesi FarmaceuticiLicensingmelatoninNeurologicalPharmaceuticalResearch

KemPharm gets $60 million funding commitment from Deerfield

KemPharm gets $60 million funding commitment from Deerfield

06-06-2014

KemPharm, a clinical-stage US biopharmaceutical company, has entered into a $60 million financing agreement…

BiotechnologyFinancialKemPharmKP201NeurologicalResearch

AFFiRiS reports breakthrough in Alzheimer's disease with AD04

AFFiRiS reports breakthrough in Alzheimer's disease with AD04

05-06-2014

Austrian biotech firm AFFiRiS has released Phase II results with its proprietary AD04 vaccine, saying…

AD04AFFiRiSBiotechnologyGlaxoSmithKlineNeurologicalResearch

1 to 25 of 317 results

Back to top